Get to know us
We started as a small interior design firm in downtown Michigan, aiming to help home buyers make do with the new space that they had acquired. It soon became obvious that it would make sense to help our clients see beyond the walls and floor plans and be there with them from the get-go. Currently, we offer house realtor, interior design, and architecture services in order to help our customers find their forever homes as seamlessly and painlessly as possible.
Why the MSC niche is the key differentiator
The Lipogems® Platform
The Lipogems® system processes adipose tissue mechanically in a closed saline loop without any enzymatic digestion. This preserves the perivascular niche structure that governs MSC behaviour and, critically, the biological cargo of the exosomes they produce.
Exosomes from niche preserved MSCs carry a more complete, more bioactive regenerative payload than those from any conventionally processed alternative.
Exosome cargo: what they carry
Niche-preserved MSC-derived exosomes carry mRNA, miRNA, growth factors (TGF-β, VEGF, IL-10), tetraspanins (CD9, CD63, CD81), and lipid rafts — the complete biological signal of regeneration.
From adipose tissue
to clinical grade
exosome therapy
Our core innovation: isolating exosomes with unique biological properties directly from the Lipogems® device without cultivation.
Platform & Science
Our core innovation: isolating exosomes with unique biological properties directly from the Lipogems® device without cultivation.
"To disrupt the field of inflammation and regenerative medicine by enabling consistent production of highly efficacious exosomes based on FDA cleared technology combined with proven, scalable biopharmaceutical manufacturing know-how."
Our mission
THE SCIENCE
Most MSC isolation methods destroy the perivascular niche — the living microenvironment that governs what exosomes carry and how effective they are. Lipogems® is the only platform that preserves it.
The Lipogems® Advantage
Scalable to GMP
Lipogems® — what it is
Derived entirely from the patient's own tissue. No allogeneic cells, no immune rejection, no disease transfer.
The Lipogems® system is a sterile, single-use Class IIa disposable medical device for the closed-loop processing and transfer of autologous adipose tissue in a single surgical step. FDA-cleared since 2014 via the 510(k) pathway.
A transparent plastic cylinder containing filters and micro-fragmentation spheres processes the harvested adipose tissue in saline immersion — removing impurities while preserving the tissue's cellular microarchitecture.
Proven Clinical Safety
Standardised process translates from clinical use to biopharmaceutical production with consistent output.
Regulated under EU MDR and US FDA with full quality system compliance and post-market surveillance.
Class IIa Medical Device
Validated in 50,000+ procedures across orthopaedics, wound care, gynaecology, and nine other specialties.
Autologous — No Rejection
FDA-cleared since 2014.
Proven in 50,000+ procedures worldwide.
Lipogems® maintains Mesenchymal Stem Cells in their native perivascular niche — a critical distinction that makes the resulting exosomes significantly more responsive to environmental stimuli and more effective upon therapeutic application than those derived from conventionally processed MSCs. Cleared by the FDA via the 510(k) pathway for orthopaedics, arthroscopy, and nine additional surgical specialties.
Where exosome therapy can make a difference
Therapeutic Applications
The Lipogems® platform has established clinical utility across a range of conditions — each representing a validated application space for Exogems' therapeutic exosomes.
